Actively Recruiting
Carotid Revascularization for Radiation Induced Carotid Artery Stenosis
Led by Xuanwu Hospital, Beijing · Updated on 2025-03-03
150
Participants Needed
2
Research Sites
416 weeks
Total Duration
On this page
Sponsors
X
Xuanwu Hospital, Beijing
Lead Sponsor
G
Guangdong Provincial People's Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
Cervical radiotherapy (RT) has greatly reduced the mortality of patients with malignant head and neck tumors, which, however, causes a higher risk of carotid artery stenosis, namely, radiation-induced carotid artery stenosis (RICS) and results in a significant increased risk of ischemic stroke. The systematic review and meta-analysis conducted by our team showed carotid endarterectomy (CEA) can yield better results for these patients than carotid artery stenting (CAS), which was contrary to most previous clinical guidelines. A large-scale prospective study is needed to verify the results. We will conduct a prospective registry of RICS patients treated with CEA to evaluate both short-term safety and long-term efficacy outcomes in a Chinese population.
CONDITIONS
Official Title
Carotid Revascularization for Radiation Induced Carotid Artery Stenosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with carotid artery narrowing who previously received radiation therapy for head and neck cancer
- The radiation treatment area included at least the neck on the same side as the carotid narrowing
- At least 1 year has passed since completing radiation therapy
- Carotid artery narrowing is confirmed by imaging tests and is greater than 50%
- Patients may or may not have symptoms; those with transient ischemic attack or stroke within 6 months are considered symptomatic
You will not qualify if you...
- Patients treated for narrowing that has returned after previous treatment (restenosis)
- Presence of brain arteriovenous malformation or aneurysm
- Severe narrowing or blockage of the brain artery on the same side
- Unstable heart conditions such as angina, heart attack, or heart failure in the past 6 months
- Uncorrectable blood clotting problems
- Uncontrolled diabetes with blood sugar over 300 mg/dL
- Pregnant or in perinatal period
- Serious other illnesses with life expectancy less than 2 years
- Allergies or intolerance to aspirin or clopidogrel
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Xuanwu Hospital, Capital Medical University
Beijing, Beijing Municipality, China, 100005
Actively Recruiting
2
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China, 510080
Actively Recruiting
Research Team
T
Tao Wang, MD
CONTACT
L
Liqun Jiao, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here